Option chain shows key data for ISHARES II PLC EUR 50 ORD by iShares II plc.'s stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ISHARES II PLC EUR 50 ORD by iShares II plc..

ISHARES II PLC EUR 50 ORD by iShares II plc. (OTC:IHIIF) Stock, Option Chain

ISHARES II PLC EUR 50 ORD by iShares II plc.

Barclays analyst Ramsey El-Assal maintains Cognizant Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) with a Overweight and raises the price target from $95 to $103.

News

Price Target

Analyst Ratings

CTSH

Barclays Maintains Overweight on Cognizant Tech Solns, Raises Price Target to $103

Northland Capital Markets analyst Nehal Chokshi reiterates Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Market Perform and lowers the price target from $150 to $146.

Reiteration

QLYS

Northland Capital Markets Reiterates Market Perform on Qualys, Lowers Price Target to $146

The acquisition enhances DocGo's offerings by leveraging PTI Health's existing partnerships and ordering platform integrations with the nation's two largest labs, and will facilitate PTI Health's expansion into new markets. Initially, DocGo plans to expand PTI Health's operations into New York City, addressing critical gaps in facilitating lab and diagnostic services in one of the nation's largest urban markets.

DCGO

DocGo Acquires PTI Health To Enhance At-Home Lab Testing And Expand Mobile Diagnostic Services Nationwide

<ul>
<li>faidr 30-day retention continues to build</li>
<li>Upgraded subscription conversion optimization platform launched last week</li>
<li>Subscription revenue guidance to be reported end of Q1</li>
</ul>

AUUD

Auddia Reports Rising faidr 30-Day Retention, Expects February To Surpass 25% As Subscription Platform Expands

Solana&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) rapid growth faces <a href="https://www.benzinga.com/money/solana-price-prediction">a significant obstacle,</a> according to Mert Mumtaz, Co-Founder and CEO of Helius Labs.
In an interview with Benzinga, Mumtaz highlighted the lack of standardized data formats, hindering actionable insights for developers and users alike.
He said the absence of uniform data schemas prevents efficient indexing and accessibility, making it difficult for different user segments to extract meaningful insights from blockchain networks.
Mumtaz identified that a primary hurdle in on-chain data lies not in technical limitations, but in the absence of universal standards. 
&#8220;The biggest hurdle in onchain data is the lack of common standards for what that data should look like,&#8221; Mumtaz stated. 
He elaborated that different users require specific data tailored to their needs, making it uneconomical to serve all use cases without standardization. 
&#8220;For data to be actionable, it must be ready to use for a specific customer-type. Stablecoins need stablecoin data. Traders need price data. NFT people need NFT data,&#8221; he said.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43570466/bitcoin-to-hit-all-time-highs-in-february-under-one-condition-standard-chartered-says">Bitcoin To Hit All-Time Highs In February Under One Condition, Standard Chartered Says</a>
To overcome this, Mumtaz advocated for establishing consistent data schemas to facilitate self-service capabilities. 
This would empower developers to access and utilize the necessary data without additional effort or customized solutions.
Mumtaz also noted the sheer scale and volume of data presents an &#8220;economic&#8221; problem as it&#8217;s not cheap to index.
Beyond data accessibility, Mumtaz also highlighted the rapid pace of Solana&#8217;s network upgrades as another developer challenge.
The rapid updates often require developers to swiftly adapt and learn new best practices to prevent their code from becoming outdated. 
Helius, according to Mumtaz, is focused on making data reading as easily and reliably as possible in the current Solana environment.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43568126/blackrock-expands-investment-in-bitcoin-heavy-strategy-reaching-5-ownership">BlackRock Expands Investment In Bitcoin-Heavy Strategy, Reaching 5% Ownership</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

Is Solana's Growth Being Held Back By A Technical Bottleneck?

Guidance

Onsemi Sees Q1 Adj. EPS $0.45-$0.55 vs. $0.89 Est., Revenue $1.35B-$1.45B vs. $1.687B Est.

This agreement grants Stardust Power the exclusive rights to utilize KMX's innovative vacuum membrane distillation technology for lithium extraction and concentration across the United States, Canada, and select international markets.

SDST

Stardust Power Executes Exclusive Licensing Agreement With KMX Technologies

<ul>
<li>Revolutionizing Diabetes Treatment: Introduction of cutting-edge, multi-targeted innovation to transform diabetes care.</li>
<li>Diabetes more than just a Metabolic Disorder: Diabetes is a multi-systemic disease impacting the central nervous system (CNS), immune function, and cellular metabolism.</li>
<li>Powerful Merger Synergies: Uniting the core competencies of both organizations in order to create a holistic solution for comprehensive diabetes management.</li>
</ul>

NLSP

NLS Pharmaceutics And Kadimastem Join Forces To Revolutionize Diabetes Treatment With Multi-Target Approach Beyond GLP-1

WIIM

onsemi shares are trading lower following worse-than-expected Q4 financial results.

Barclays analyst Ramsey El-Assal maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and raises the price target from $75 to $85.

AFRM

Barclays Maintains Overweight on Affirm Holdings, Raises Price Target to $85

Earnings

Earnings Misses

ON Semiconductor Q4 2024 Adj. EPS $0.95 Misses $0.97 Estimate, Sales $1.722B Miss $1.758B Estimate

Stifel analyst Daniel Arias maintains Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) with a Buy and lowers the price target from $28 to $26.

AVTR

Stifel Maintains Buy on Avantor, Lowers Price Target to $26

Gas Supply Expected to Generate Up to 1.2 Gigawatts of Direct Power to AI-Focused Data Center

Energy Transfer To Supply Natural Gas For CloudBurst's AI Data Center In Texas, Powering Up To 1.2GW

CENX

STLD

Shares of steel and aluminum stocks are trading higher after reports President Trump plans additional 25% tariffs on steel and aluminum.

Barclays analyst Adam Seiden maintains Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) with a Equal-Weight and lowers the price target from $60 to $52.

Barclays Maintains Equal-Weight on Terex, Lowers Price Target to $52

Billionaire Bill Gates said in an interview last week that he is not a &#8220;Mars person&#8221; like Jeff Bezos or Elon Musk, saying he would rather continue to put his wealth into funding better nutrition and getting rid of diseases like malaria.
What Happened: &#8220;I am not a big Mars person,&#8221; Gates said in an interview with Ashley Christine published on YouTube on Friday while adding that he does not believe Earth&#8217;s neighboring planet is a &#8220;very hospitable place.&#8221;
Gates commended Musk and Bezos for their attempts at making space launches less expensive by reusing parts of the launch vehicle. 
&#8220;That&#8217;s a pretty great contribution because there are things that you want to do in space like putting up communication satellites like the Starlink service&#8230;,&#8221; he said. While Musk is the founder of space tech company SpaceX, Bezos is the founder of Blue Origin.
However, Gates is unsure about enabling human existence in space or on Mars. &#8220;&#8230;we&#8217;re not sure can we can put solar panels in space can (or) we put data centers in space (or) can we do chemical Manufacturing in space&#8230;,&#8221; he said.
Why It Matters: This is not the first time that Gates has expressed a lack of interest in space exploration.
&#8220;I don't think rockets are the solution. But maybe I&#8217;m missing something there,&#8221; <a href="https://www.benzinga.com/news/23/08/33660308/bill-gates-says-unlike-elon-musk-im-not-a-mars-person-and-would-rather-spend-money-on-vaccines-than">he said during an appearance</a> on Kara Swisher&#8217;s &#8220;Sway&#8221; podcast in 2023. 
Gates, Bezos, and Musk are among the<a href="https://www.benzinga.com/news/global/24/12/42406893/bill-gates-could-go-bankrupt-if-tesla-stock-surges-200-to-become-the-top-company-says-elon-musk"> top ten rich people</a> around the globe. While Musk tops the chart with a total net worth of $402 billion, Bezos is in the third position with a total net worth of $249 billion and Gates in the seventh position with a total net worth of $165 billion, according to the Bloomberg Billionaires Index.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43585701/tesla-ceo-elon-musk-vp-of-finance-address-allegations-of-tax-fraud-losses-were-high-for-many-years-so-carry-forward">Tesla CEO Elon Musk, VP Of Finance Address Allegations Of Tax Fraud: &#8216;Losses Were High For Many Years, So Carry Forward&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Bill Gates Would Rather Save Earth Than Colonize Mars — Unlike Elon Musk, Jeff Bezos: 'I'm Not a Big Mars Person… It's Not a Very Hospitable Place'

TMUS

T-Mobile shares are trading higher after the company's Starlink beta rollout expanded nationwide.

Offerings

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Receives Binding Commitments For Capital Raising Of A$40M Via Two Tranche Placement Of Fully Paid Ordinary Shares

Barclays analyst Balaji Prasad maintains Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Underweight and raises the price target from $20 to $22.

PAHC

Barclays Maintains Underweight on Phibro Animal Health, Raises Price Target to $22

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Overweight and raises the price target from $310 to $329.

Comments

ISHARES II PLC EUR 50 ORD by iShares II plc.

ISHARES II PLC EUR 50 ORD by iShares II plc. (IHIIF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga